Rokos Capital Management (UK)’s CRISPR Therapeutics CRSP Stock Holding History

Rokos Capital Management (UK)’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-87,500	Closed	-$4.07M	–	79
2023 Q3	$4.07M	Hold	87,500	–	–	0.03%	87
2023 Q2	$4.9M	Hold	87,500	–	–	0.05%	73
2023 Q1	$3.95M	Hold	87,500	–	–	0.29%	41
2022 Q4	$3.49M	Hold	87,500	–	–	0.15%	49
2022 Q3	$5.87M	Hold	87,500	–	–	0.17%	60
2022 Q2	$5.5M	Hold	87,500	–	–	0.16%	59
2022 Q1	$5.61M	Buy	+87,500	New	+$5.49M	0.26%	46

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Rokos Capital Management (UK)'s CRSP Position: Q4 2023 in Review

Rokos Capital Management (UK) sold out of CRISPR Therapeutics (CRSP) in Q4 2023, closing a stake of 87,500 shares — an estimated $4.07M sold.

Rokos Capital Management (UK) first reported a position in CRSP in Q1 2022 and held it in 7 quarters. The position peaked at $5.87M in Q3 2022. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

Rokos Capital Management (UK) reported no remaining CRISPR Therapeutics position as of Q4 2023 after selling out during the quarter.
Rokos Capital Management (UK) sold 87,500 CRISPR Therapeutics shares in Q4 2023, an estimated $4.07M.
Rokos Capital Management (UK) first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 7 quarters.
Rokos Capital Management (UK)'s CRISPR Therapeutics position peaked at $5.87M in Q3 2022.
472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Rokos Capital Management (UK)'s 13F filing for Q4 2023, filed 14 Feb 2024.